Efficacy of intranasal corticosteroids on the ocular symptoms of allergic rhinitis

被引:1
|
作者
Demoly, P. [1 ]
Klossek, J. M. [2 ]
Serrano, E. [3 ]
Didier, A. [4 ]
机构
[1] CHU Montpellier, Hop Arnaud de Villeneuve, INSERM, Serv Pneumol & Allergol,U657, F-34295 Montpellier 05, France
[2] CHU Poitiers, Hop Jean Bernard, Serv ORL, F-86021 Poitiers, France
[3] Hop Larrey, Serv ORL, F-31059 Toulouse 9, France
[4] CHU Toulouse, Hop Larrey, Serv Pneumol Allergol, F-31059 Toulouse 9, France
来源
REVUE FRANCAISE D ALLERGOLOGIE | 2010年 / 50卷 / 05期
关键词
Allergic rhinitis; Ocular symptoms; Intranasal corticotherapy; Furoate; FUROATE NASAL SPRAY; FLUTICASONE FUROATE; SUBLINGUAL IMMUNOTHERAPY; RECEPTOR ANTAGONISTS; DOUBLE-BLIND; SAFETY; MANAGEMENT; POLLEN; PROPIONATE; CHALLENGE;
D O I
10.1016/j.reval.2010.03.002
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Allergic rhinitis (AR) is the most prevalent allergic disease. AR seriously affects the quality of life of patients who suffer from this condition, and it also affects their professional and social activities. Ocular symptoms represent a major component of AR and their importance is often underestimated. The pathophysiology of the ocular symptoms of AR has been studied extensively over the last decade. Intranasal corticosteroids are without a doubt effective in alleviating these ocular symptoms. Mometasone furoate and fluticasone furoate nasal sprays, in particular, are two new topically-active corticosteroids whose efficacy on ocular symptoms has been demonstrated in prospective studies in patients with seasonal and/or perennial AR. Drug treatment of AR can therefore be based on the administration of intranasal corticosteroid which, when combined with allergen avoidance and eye washes, should provide optimal benefit while minimizing cost and pharmaceutical risks. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:419 / 425
页数:7
相关论文
共 50 条
  • [31] Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis
    Rami Jean Salib
    Peter Hugo Howarth
    Drug Safety, 2003, 26 : 863 - 893
  • [32] Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis
    Blaiss, Michael S.
    ALLERGY AND ASTHMA PROCEEDINGS, 2011, 32 (06) : 413 - 418
  • [33] Cochrane corner: Intranasal corticosteroids for non-allergic rhinitis
    Gregory, Ian
    Grewal, Anjum
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (07): : 836 - 838
  • [34] Steroid sparing effects of intranasal corticosteroids in asthma and allergic rhinitis
    Nair, A.
    Vaidyanathan, S.
    Clearie, K.
    Williamson, P.
    Meldrum, K.
    Lipworth, B. J.
    ALLERGY, 2010, 65 (03) : 359 - 367
  • [35] The Impact of Intranasal Corticosteroids on Lung Function in Children With Allergic Rhinitis
    Kessel, Aharon
    PEDIATRIC PULMONOLOGY, 2014, 49 (09) : 932 - 937
  • [36] Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis
    Schaefer, T.
    Schnoor, M.
    Wagenmann, M.
    Klimek, L.
    Bachert, C.
    RHINOLOGY, 2011, 49 (03) : 272 - 280
  • [37] The impact of intranasal corticosteroids on lung function in children with allergic rhinitis
    Lozano, Alejandro
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2014, 112 (04): : E172 - E172
  • [38] The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome
    Taramarcaz, P
    Gibson, PG
    CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (12): : 1883 - 1889
  • [39] OCULAR SYMPTOM EFFICACY AND INTRANASAL CORTICOSTEROIDS Response
    Bielory, Leonard
    Gross, Gary
    Georges, George
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (06) : 539 - 540
  • [40] The efficacy of intranasal antihistamines in the treatment of allergic rhinitis
    Kaliner, Michael A.
    Berger, William E.
    Ratner, Paul H.
    Siegel, Charles J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 106 (02) : S6 - S11